March 25, 2026 7:58am

As President Trump sees the possibility of diplomacy as his comments signal a possible Iran de-escalation. Yesterday all 3 major averages posted losses, “uncle algo and his electronic trading dwarfs” are thirsting after the oversold

As I wrote in Monday’s closing bell, “Digging through the ruble of share pricing on Tuesday. … I am STILL a wait and HOLD!”

Pre-open Signals: 7 Positive indications

News:  Beam Therapeutics (BEAM +$2.25 or +9.39% to $26.20 pre-open) updated safety and efficacy data from the ongoing P1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval. BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation designed to directly correct the underlying genetic mutation that causes the severe form of alpha-1 antitrypsin deficiency (AATD) through base editing. AATD is a serious genetic disease that can lead to significant liver disease.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

Say/write less, mean more …

 

RMi Closing Bell: A slight comeback, with an indecisive purge after Monday’s surge … https://www.regmedinvestors.com/articles/14359

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Tuesday: The pre-open Dow futures are UP +1.09% or (+507 points), the S&P futures are UP +1.03% or (+67.75 points) and the Nasdaq futures are UP +1.22% or (+294 points)

  • U.S. stock futures are on the rise due to possible progress with Iran, Wednesday, 3/25
  • European equities and bourses opened higher,
  • Asia Pacific markets were on the move upward as oil began to flow

 

Economic Data: It’s still all about oil pricing

  • 8:30 am                Import price index - Feb.                              
  • 8:30 am                Import price index minus fuel - Feb.
  • 4:10 pm               Fed governor Stephen Miran speaks

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed DOWN -84.41 points or -0.18%, the S&P closed DOWN -24.63 points or -0.37% while the Nasdaq closed DOWN -184.865 points or -0.84%
  • Monday: The Dow closed UP +631.12 points or +1.38%, the S&P closed UP +74.52 points or +1.15% while the Nasdaq closed UP +299.149 points or +1.38%
  • Friday: The Dow closed DOWN -443.96points or -0.96%, the S&P closed DOWN -100.01 points or -1.51% while the Nasdaq closed DOWN -443.08 points or -2.01%
  • Last week: the S&P 500 lost 1.5%, the Dow and Nasdaq fell around 2%
  • The previous week: The S&P 500 was down -1.6%, the Dow -2% and the Nasdaq was down -1.3%.
  • February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.

 

Q1/26 – Q1 – March – 7 positive and 10 negative closes

  • February – 1 market holiday, 11 positive and 8 negative closes
  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Watch and listen

  • Vertex (VRTX) closed down -$2.61 after Monday’s +$2.85 with a positive +$3.08 or +0.69% pre-open
  • BioNTech (BNTX -$1.60 after Monday’s -$0.86 with a positive +$1.35 or +1.56% pre-open
  • Capricor Therapeutics (CAPR) closed down -$1.23 after Monday’s +$1.00 with a positive +$0.10 or +10.35% pre-open
  • Ionis Pharmaceuticals (IONS) closed down -$1.11 after Monday’s -$0.20 with a positive +$0.52 or +0.75% pre-open
  • IQVIA Holdings (IQV) closed down -$0.87 after Monday’s +$0.93 with a positive +$2.81 or +1.69% pre-open
  • uniQure NV (QURE -$0.74 with a positive +$0.42 or +2.77% pre-open

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

My thoughts … OPEN the wallet – BUY - selectively!

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

March – 4th week:

  • 3/24 – Tuesday closed negative with 11 incliner, 26 decliners and 3 flats
  • 3/23 - Monday closed positive with 26 incliners, 12 decliners and 2 flats

March – 3rd week

  • 3/20 – Friday closed negative with 6 incliner, 33 decliners and 1 flat
  • 3/19 – Thursday closed positive with 20 incliners, 18 decliners and 2 flats
  • 3/18 – Wednesday closed negative with 3 incliner, 35 decliners and 2 flats
  • 3/17 - Tuesday closed positive with 25 incliners, 14 decliners and 1 flat
  • 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.